Presenting our precise clinical experience with HOO-IMM PLUS treatment for acute and
chronic viral Hepatitis.
HOO-IMM PLUS polyherbal formulation consists of a number of active molecules of
different plant species act on multiple targets against HBV.
To buy https://posts.gle/ahLSy6
Glycyrrhiza Glabra :
Glycyrrhizin, a major component of a herb (licorice), has been widely used to
treat chronic hepatitis B in Japan. This substance improves liver function with
occasional complete recovery from hepatitis
Its effects on the secretion of hepatitis B surface antigen (HBsAg) were examined
in vitro. Glycyrrhizin suppressed the secretion of HBsAg and accumulated it
dose-dependently in PLC/PRF/5 cells.
Phyllanthus Niruri :
An aqueous extract of the plant Phyllanthus niruri inhibits endogenous DNA
the polymerase of hepatitis B virus and binds to the surface antigen of hepatitis B
virus in vitro.
Phyllanthus significantly reduced serum HBV DNA (a marker of efficacy) as well
as HBeAg (a marker of viral replication).
A potential anti-HBV agent, ellagic acid, was isolated from the medicinal plant P.
niruri, and its physicochemical properties were characterized.
Phyllanthus niruri (Bhumyamalaki) had the ability to inhibit HBV polymerase to
decrease episomal HBV DNA content by downregulating HBV messenger RNA
transcription.
Terminalia Chebula :
Studied and found that 90% of Terminalia chebula ethanolic extracts inhibited on
HBs antigen-binding assay and HBV DNA polymerase inhibition assay.
In silico analysis of potent compounds from Terminalia chebula proved to be
effective against Hepatitis B virus.
In HBs antigen-binding assay, the lyophilized ethanolic extracts of Terminalia
chebula exhibited 60% of maximum inhibition whereas the aqueous extracts
showed 55% of inhibition and the control lamivudine exhibited 60% of inhibition
Cucurma Longa :
Curcumin treatment led to time- and dose-dependent reductions in HBsAg and
HBeAg expression and significant reductions in intracellular HBV DNA
replication
Andrographis Panicula :
Dehydroandrographolide and andrographolide, two natural diterpenoids isolated
from Andrographis paniculata possessed activity against HBV DNA replication
Failed Tenofovir Treatme
Several anti-viral those are currently available for the treatment of HBV which
includes IFN alpha, Lamuvidine, Entecavir, Telbibudine and Tenofovir.
Interferon therapy has limited efficacy, slow-acting, and frequently causes adverse
effects. Undesirable side effects of interferon treatment are found such as fever,
malaise, fatigue, depression, hair loss, neutropenia, and thrombocytopenia.
On the other hand, the side effects of Tenofovir are no less than Interferon. The
common side effects include fever, pain, diarrhea, vomiting, depressed mood,
rashes, insomnia. Moreover, the anti-viral drug and Interferon are expensive.
Moreover, if the patient drops the Tenofovir medication even for 48 hours the
HBV viral load elevates to 10 3 .
HBV DNA Quantitative
Quantification of HBV DNA reflects the viral load which plays a critical role in
determining the phase of infection, deciding the treatment, and determining the
response to anti-viral treatment.
Case 1: Patient dropped Tenofovir
In this present study, HBV patients receiving conventional Tenofovir had to drop
the treatment due to poor compliance (developing jaundice within the interval of
15 days and incidence of elevated SGPT & SGOT level) also virological relapse
after cessation of Tenofovir therapy.
The patients discontinued the Tenofovir
therapy due to side effects and went on HOO-IMM PLUS therapy.
Further, the patient followed up every 3 months for monitoring and within the
interval of 4-6 months HBV DNA Quantitative level were monitored.
After the cessation of Tenofovir therapy for 21 days, the mean HBV DNA level
was 5.7 log IU/ml. With the follow up of HOO-IMM PLUS treatment in the first
6 months the mean HBV DNA level was 3.5 log IU/ml and the treatment was
continued for 12 months reported Target Not Detected for HBV DNA
Quantification.
Case 2: Drug naïve HBV individual receiving HOO-IMM PLUS
In this present study, the patient never had any medication pertaining to HBV
infection, received HOO-IMM PLUS therapy, they showed good compliance and
virological suppressions right after few weeks of treatment. The patients
continued the therapy due to the viral decline in the first 4 months of the treatment.
Furthermore, they followed up for 12 months and they were monitored in the
interval of 4 months.
The mean HBV DNA level initially found to be 6.6 logs IU/ml that has been
declined to mean 3.7 log IU/ml in the first 4 months of the treatment to mean 1.46
log IU/ml in the next 4 months of the treatment followed by Target Not Detected
in the 12th month monitoring. Moreover, there is a regulated normal liver enzyme
throughout the treatment.
Normal Liver Function
Hooimm Plus prevents liver injury from viral hepatitis. HBV individuals
receiving Hooimm plus treatment having normalized liver enzyme. The treatmen
prognosis reports normal level of the routine test of Serum Alanine
Aminotransferase (ALT) or Serum glutamic pyruvic transaminase (SGPT) and
Aspartate Aminotransferase (AST). AST and SGPT is a blood test that checks for
the liver damage. SGPT and AST levels in the blood rise if your liver is damaged.
Biomarker or Test protocol involved in the anti-hbv treatment with Hooimm
plus:-
- HBV Serological markers which include HBsAg & HBeAg Elisa.
- Serum Alanine Aminotransferase (ALT) or Serum glutamic pyruvic
transaminase (SGPT) & Aspartate Aminotransferase (AST) or SGOT. - HBV DNA Quantification-Viral Load.
Preventing viral-induced Carcinoma
The HOO-IMM PLUS constitute curcumin molecule which has been proven a
star key molecule in preventing hepatocellular carcinoma.
The HOO-IMM PLUS constitutes a curcumin molecule that has been proven a
star key molecule in preventing hepatocellular carcinoma. Much research has
been done on curcumin suggesting that it inhibits proliferation induces apoptosis,
potentiate attenuates ROS. But the poor systemic absorption of curcumin is major
the obstacle for its efficacy. Here we have a unique extraction procedure for Curcuma
longa which yields curcumin with high degree bioavailability and along with
other herbal extract formulation that improves the gut absorption of curcumin.